Delivery Order SPE2DB20D2014-SPE2DB25FC71Q
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,542.97 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. As a child delivery order under a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a quantity of 90 tablets, with a contract ceiling value of $1,393.20. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Valsartan-HCTZ 80-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, valued at $3,321.82, represents a non-competitive set-aside contract and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $2,484.03. This is a firm fixed price delivery order with no set-aside designation, issued as a competitive award. The place of performance is AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) valued at $5,573.64. This is a firm fixed-price delivery order with no set-aside designation, and the product is scheduled for delivery by July 29, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $1,697.07. This competitively awarded, firm fixed-price contract is classified as non-set-aside and was completed on August 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the delivery order from its location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,214.05 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90s, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $36,196.14 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was awarded without set-aside designation through competitive procedures and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,733.29 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count bottles) under a firm fixed-price contract. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 90 units of the pharmaceutical product Valsartan-HCTZ 320-25 mg tablets. The contract has a completion date of February 5, 2024 and a potential value of $1,295.24. AmerisourceBergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation or larger contract...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC71QDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,294.61 to AmerisourceBergen Drug Corp for the supply of Valsartan-Hydrochlorothiazide 320-25 mg tablets (90-count supply) under a firm fixed price contract type. The order, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is issued as a child contract under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion vehicle designated SPE2DX and running through December 2026. The Valsartan-Hydrochlorothiazide procurement reflects the Defense Logistics Agency's ongoing pharmaceutical supply chain management for military healthcare operations. AmerisourceBergen's comprehensive IDC with DLA enables the company to fulfill diverse pharmaceutical requirements across multiple therapeutic domains, including cardiovascular medications such as this antihypertensive combination product. The delivery order underscores the critical role pharmaceutical distributors play in supporting Department of Defense health services and demonstrates the agency's reliance on established vendor relationships to meet recurring medical supply demands efficiently.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 8/12/25 |